Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université de Montréal

$18,000.00

Revisiting pharmacological concepts and quantitative techniques where nonlinearity and variability are critical

FY 2017-18

Summary
Variability and nonlinearity are the two main factors that determine the drug fate in a complex biological system. Because of the paucity of measuring and computing techniques, the community of clinical pharmacology has long been restricted to linear deterministic or simple summary statistical methodologies. However, nowadays drug discovery provides strong evidence for the decisive roles of these two factors in drug kinetics and dynamics. Ignoring variability and nonlinearity when developing drug mathematical models, has been proved to be one reason producing biased predictions out of observed ranges of targeted phenomena. This situation has been changed with the introduction of the population pharmacokinetics/pharmacodynamics modeling approach (Nonlinear Mixed Effect Models) more than two decades ago. With the intention to describe the evolution of drug plasma concentrations and therapeutic effects in a patient population, this new approach successfully introduced different levels of variability within the previously deterministic context defined with ordinary differential equations, and set up the context for the quantitative era of pharmacology, where mathematics are gaining more ground and mathematicians becoming one of the principal actors. Facing this reality, many pharmacological concepts and methods developed using linear and deterministic principles should be revisited and mathematically revised taking into account the drug related nonlinearity and variability. With the identified three axis, nonlinearity in drug pharmacokinetics, variability in drug intake and therapeutic outcomes, and improvement of drug evaluation issues in the context of variability, the current research program will help to intensify this quantitative trends of pharmacology where mathematics is in the central position but also benefits from new raised problematics. The contribution of the current NSERC discovery grant will be used to investigate various aspects in this direction.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2016-05058
Name nom
Li, Jun
Department département
Pharmacie, Faculté de - Pharmacie, Faculté de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
18000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1508
Committee name en
Mathematics and Statistics
Committee name fr
Mathématiques et statistique
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
2950
Research subject group en
Applied mathematics
Research subject group fr
Mathématiques appliquées
Research subject en
Applied mathematics
Research subject fr
Mathématiques appliquées
Partie
2
Nb partie
5
Application title
Revisiting pharmacological concepts and quantitative techniques where nonlinearity and variability are critical
Keyword
NSERC
Application summary
Variability and nonlinearity are the two main factors that determine the drug fate in a complex biological system. Because of the paucity of measuring and computing techniques, the community of clinical pharmacology has long been restricted to linear deterministic or simple summary statistical methodologies. However, nowadays drug discovery provides strong evidence for the decisive roles of these two factors in drug kinetics and dynamics. Ignoring variability and nonlinearity when developing drug mathematical models, has been proved to be one reason producing biased predictions out of observed ranges of targeted phenomena. This situation has been changed with the introduction of the population pharmacokinetics/pharmacodynamics modeling approach (Nonlinear Mixed Effect Models) more than two decades ago. With the intention to describe the evolution of drug plasma concentrations and therapeutic effects in a patient population, this new approach successfully introduced different levels of variability within the previously deterministic context defined with ordinary differential equations, and set up the context for the quantitative era of pharmacology, where mathematics are gaining more ground and mathematicians becoming one of the principal actors. Facing this reality, many pharmacological concepts and methods developed using linear and deterministic principles should be revisited and mathematically revised taking into account the drug related nonlinearity and variability. With the identified three axis, nonlinearity in drug pharmacokinetics, variability in drug intake and therapeutic outcomes, and improvement of drug evaluation issues in the context of variability, the current research program will help to intensify this quantitative trends of pharmacology where mathematics is in the central position but also benefits from new raised problematics. The contribution of the current NSERC discovery grant will be used to investigate various aspects in this direction.